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H I G H L I G H T S
• Patients with IAS-defined “severe” FH (SFH) are at highest risk of future CHD.• In the UK Simon Broome FH Register ∼70% meet the SFH criteria.• Those with SFH have 64% higher CHD mortality than non SFH patients.• This is explained by their higher classical risk factors including untreated LDL-C.





A B S T R A C T
Background and aims: The International Atherosclerosis Society (IAS) has proposed that patients with “severe”
FH (SFH) would warrant early and more aggressive cholesterol-lowering treatment such as with PCSK9 in-
hibitors. SFH is diagnosed if LDL-cholesterol (LDLC) > 10mmol/L, or LDLC>8.0mmol/L plus one high-risk
feature, or LDLC>5mmol/L plus two high-risk features. Here we compare CHD mortality in SFH and non-SFH
(NSFH) patients in the UK prospective Simon Broome Register since 1991, when statin use became routine.
Methods: 2929 definite or possible PFH patients (51% women) aged 20–79 years were recruited from 21 UK lipid
clinics and followed prospectively between 1992 and 2016. The excess CHD standardised mortality ratio (SMR)
compared to the England and Wales population was calculated (with 95% confidence intervals).
Results: 1982 (67.7%) patients met the SFH definition. Compared to the non-SFH, significantly (p<0.001) more
SFH patients had diagnosed CHD at baseline (24.6% vs. 17.5%), were current smokers (21.9% vs 10.2%) and had
a BMI > 30 kg/m2 (14.9% vs. 7.8%). The SMR for CHD mortality was significantly (p=0.007) higher for SFH
(220 (184–261) (34,134 person years, 129 deaths observed, vs. 59 expected) compared to NSFH of 144 (98–203)
(15,432 person years, 32 observed vs. 22 expected). After adjustment for traditional risk factors, the Hazard
Ratio for CHD mortality in SFH vs. NSFH was 1.22 (0.80–1.87) p=0.36, indicating that the excess risk was
largely accounted for by these factors.
Conclusions: CHD mortality remains elevated in treated FH, especially for SFH, emphasising the importance of
optimal lipid-lowering and management of other risk factors.
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Familial hypercholesterolaemia (FH) is a common autosomal
dominant disorder caused by carriage of a mutation in one of several
genes known to be involved in clearance of low-density lipoprotein
cholesterol (LDL-C) particles from the blood [1,2]. The elevated levels
of LDL-C from birth mean that patients with FH have a very high risk of
developing coronary heart disease (CHD) at an early age [3–5]. In 2016,
the International Atherosclerosis Society proposed that patients with
“severe” FH (SFH) should be identified [6] since they might warrant
early and more aggressive cholesterol-lowering treatment (e.g., with
proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors). SFH
is diagnosed if the patient has LDL-cholesterol (LDL-C)> 10mmol/L or
LDL-C> 8.0mmol/L plus one high-risk feature or LDL-C>5mmol/L
plus two high-risk features. High-risk features are age> 40 years
without treatment, smoking, male sex, lipoprotein(a) > 75 nmol/L,
hypertension, diabetes mellitus, family history of early CHD in first-
degree relatives, chronic kidney disease, and BMI> 30 kg/m2 [6].
Here we compare the standardised mortality ratio (SMR) for CHD in
SFH and non-SFH patients in the UK prospective Simon Broome
Register, which has been following FH patients since 1988 for CHD and
non-CHD causes of death [7–10]. We use this data to estimate the SMR
for CHD in SFH vs. Non-SFH (NSFH). The Simon Broome Registry ca-
tegorises those with elevated LDL-C and early family history of heart
disease and with tendon xanthomas as “definite FH (DFH)” and those
with no tendon xanthomas as “possible FH (PFH)”, with CHD mortality
being higher in DFH compared to PFH patients [7–10], and we compare
CHD mortality rates in those with SFH and DFH vs. PFH. We examine
whether the CHD risk associated with SFH is similar in men and
women, and we estimate the risk of CHD in SFH in different age groups,
and to what extent the CHD SMR rates fall over time in SFH as potent
statins become available. Finally, we estimate the extent to which the
higher CHD mortality risk in SFH patients is explained by the included
classical risk factors.
2. Materials and methods
The methods have been described previously [7–10]. The char-
acteristics of patients at registration were recorded on a standard re-
gistration form. A fasting venous blood specimen taken at the regis-
tration visit was used to determine serum total cholesterol,
triglycerides, and high density lipoprotein, and was measured by the
laboratories routinely used by the participating clinics. LDL-C con-
centrations were calculated using the Friedewald formula [11]. Regis-
tered patients were flagged by the National Health Service Central
Registry and, in the event of death, a copy of the death certificate was
provided. The underlying cause of death was coded by one investigator
using the International Classification of Disease (ICD) 9th revision. All
patients gave informed consent for inclusion in the Register. The study
received approval from the local ethics committee of each participating
centre. Patients were classified as having either Simon Broome (SB)
definite FH or possible FH, using published criteria previously [7–10],
and by using the proposed severe FH criteria as described above and in
Ref. [6]. Hypertension was defined as self-reported hypertension, and
family history of early CHD in first-degree relatives was defined as re-
corded CHD under the age of 55 years in a male and 60 years in a
female first-degree relative. Lipoprotein(a) and creatinine measures
were not available in the majority of subjects so these variables were
not included.
The analysis used a standard computer program for cohort studies
[12]. Person-years of risk were aggregated into 5-year age groups and
5-year calendar periods and the expected number of deaths from spe-
cified causes were estimated. A total of 571 subjects were censored on
reaching the age 80 years, and a further 50 patients who had emigrated
were censored at the date of embarkation. The expected number of
deaths from CHD (ICD codes 4100–4149) were calculated by applying
the age and calendar-specific death rates for men and women in the
general population of England and Wales to the person years (pyears)
accumulated by men and women in the cohort. The standardised
mortality ratio (SMR) was calculated from the ratio of the number of
deaths observed to those expected, and was expressed as a percentage
(SMR=100 for the reference population), and the exact 95% con-
fidence intervals were calculated. The test of significance used was a
two-sided Poisson probability of observing the number of deaths that
occurred given the expected number of deaths. A Cox-proportional
hazard model was used to identify univariate baseline characteristics
that were significantly associated with CHD mortality, and a stepwise
model used to identify those that were independently associated using a
significance level of 0.05 for entry to the model and 0.10 for elimina-
tion. A term for SFH/NSFH was forced into the model to examine
whether the higher risk in SFH patients was explained by these factors.
Main analyses were conducted on data obtained post 1991 in order to
estimate CHD mortality in statin-treated patients. We also included the
period 1980–91 in the analysis to examine the change in CHD mortality
over time i.e. pre and post-statins. To do this, we divide the follow-up
periods into that before January 1992, when statins were not routinely
used, between January 1992–December 2008, during which time statin
treatment became widely available, and from 2009 to December 2015,
when it would be expected that FH patients would have their LDL-C
levels managed with high potency statin treatment and or combination
therapy with other lipid lowering agents such as ezetimibe.
3. Results
Of the 2929 registered patients with the required data, 201 (7.2%)
had LDL-C>10.0mmol/l, 423 (14.4%) had LDL-C below 10mmol/l
but above 8mmol/l, and 1809 (61.8%) had LDL-C below 8mmol/l but
above 5.0 mmol/l (Supplementary Table 1), with 496 (16.9%) having
LDL-C levels below 5.0mmol/l. All of those with LDL>10mmol/l
fulfil the SFH definition, while 96.6% (n=409) of those with LDL-
C<10mmol/l but> 8mmol/l had one or more high risk factor and
75.8% (n=1372) of those with LDL-C< 8mmol/l but> 5.0mmol/l
had two or more high risk factors. In total, 1982 (67.7%) met the SFH
definition. As shown in Table 1, compared to the NSFH group, sig-
nificantly (all p<0.001) more of those with SFH had diagnosed CHD
(24.6% vs. 17.5%), were current smokers (21.9% vs. 10.2%) and had a
BMI > 30 kg/m2 (14.9% vs. 7.8%). The prevalence of diabetes was low
in both groups (1.0% vs. 0.6%). Compared to the NSFH patients, a
significantly higher proportion of the SFH group had an SB clinical
diagnosis of DFH (55.8% vs. 49.5% p=0.02).
Overall, there were 185 deaths from CHD. As shown in Fig. 1A, post
1991, in those with SFH, the SMR for CHD mortality was 64% higher
(220 (184–261) compared to non-SFH of 144 (98–203) (p=0.007). As
shown in Supplementary Table 2, for those with SFH, the SMR for CHD
mortality was significantly higher in those with a Simon Broome di-
agnosis of definite FH compared to those with possible FH (255
(202–318) vs. 179 (133–237), p=0.05). By contrast, in those with non-
SFH, there was no difference in the SMR in definite vs. possible FH
patients (Supplementary Table 2). The overall ten-year CHD mortality
rate (Kaplan-Meier estimate) for NSFH at baseline was 1.5% and for
SFH was 3.5%. After adjusting for age, this equated to a rate of 0.5% at
age 40, 1.3% at age 50 and 3.1% at age 60 for those with NSFH, with
rates in those with SFH being 2.2%, 3.7% and 6.2% respectively.
A substantially elevated SMR for CHD in SFH was observed in both
males (237 (192–290) and females (226 (169–296)), while in NSFH, the
SMRs were lower but still statistically significantly higher in males (168
(106–251) but not in females (109 (56–190)) (Supplementary Fig. 1).
We also estimated the CHD SMR in SFH males and females by age ca-
tegories at registration, and data are presented in Fig. 1B. In both males
and females in the age range 20–39 years, the SMR was extremely high
but the number of observed events was very low and the confidence
intervals large. In the 40–59 year age range, where numbers of
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observed deaths is higher, the SMR in males was 367 (263–501)
(10,483 pyears; 40 deaths vs. 10.8 expected) and in females was
611v305-1093) (6194 pyears; 11 deaths vs. 1.8 expected). In the older
age group of 60–79 years, the SMR had fallen but remained statistically
significant (males 167 (124–221), 5983 pyears; 49 deaths vs. 29 ex-
pected, females 179 (127–246) 7998 pyears; 21 deaths vs. 8 expected).
Separate analyses for CHD mortality were carried out for the period
before January 1992, between January 1992–December 2008, and from
2009 to December 2015. Over the three time periods in general, SMR
mortality fell in each age category as expected (Supplementary
Table 3). As shown in Fig. 1C and Table 2, in males with SFH, there was
significant excess coronary mortality in the first two periods, falling
from an SMR of 356 (178–637) to 255 (198–232), but post 2008 CHD
mortality was no longer statistically significant (159 (91–258)). By
comparison in females, although the initial high rate pre 1992 fell from
498 (215–982) to 173 (117–247) in the 1992–2008 period, the SMR
was high post 2008 (350 (192–588). In NSFH patients, the CHD SMRs
were low at all time periods in both males and females and only reached
statistical significance in males in the 1992–2008 period (183
(107–293)).
Finally, we determined to what extent the excess SFH-associated
CHD mortality risk was explained by traditional risk factors. As shown
in Table 3, CHD mortality risk was independently related to age, sex,
smoking, previous CHD and total cholesterol level at registration and,
of these, prior CHD was associated with the largest HR. Overall, the
hazard ratio for CHD in SFH vs. NSFH was 1.93 (1.33–2.79) p=0.0005
before adjustment and 1.22 (80–187) p=0.36 after adjustment for all
variables in the stepwise model.
4. Discussion
In the UK Simon Broome FH Register, 67.7% of patients fulfil the
IAS definition of SFH, based on their baseline characteristics. High le-
vels of Lp(a) and creatinine are also components of the SFH definition
[6], but were not available for this cohort, and a proportion of the NSFH
patients would be moved to the SFH category if this data were avail-
able, so this figure is an underestimate of the true prevalence of SFH in
this cohort. The data show that, despite current treatments, CHD
mortality is markedly elevated in SFH patients and supports the view
that attaining optimal lipid lowering, as well as management of other
risk factors, will be of clinical benefit. The data provide an evidence
base for the IAS proposed categorisation [6], and for the subsequent
stratified management of those with non-severe and severe-FH. The
high CHD risk in treated SFH was of similar magnitude in both men and
women (with an SMR of 237 and 226 respectively), but while the CHD
risk was elevated in treated NSFH men (SMR of 168), this was not the
case in NSFH women (SMR of 109), suggesting that CHD risk in the
majority of this group is being appropriately treated.
Overall, the hazard ratio for CHD in SFH was 64% higher than in
NSFH, with CHD mortality risk being independently related to age, sex,
smoking, previous CHD, total cholesterol and age above 40 years and
untreated at diagnosis, with the major determinant of risk being a prior
diagnosis of CHD. After adjustment for these variables in a stepwise
model, the mortality risk in SFH and NSFH was not significantly dif-
ferent, indicating that the excess risk in the SFH patients can be ac-
counted for mainly by these risk factors. These data reinforce that early
diagnosis, before CHD has occurred, is likely to be of major benefit in
reducing morbidity in subjects with FH. We have previously reported
that, except for low HDL-C, a range of novel and emerging CHD risk
factors were not independently associated with CHD risk in this cohort
[13]. Overall, the ten year CHD mortality rate for SFH at baseline was
around 2-fold higher than for those with NSFH, with similar fold dif-
ferences over the whole age range. The SMR for CHD was extreme in
both men and women in the 20–39 year old age range, but the number
of events is small and the CIs were large. In middle age, the CHD SMRs
were over 350 in men and 500 in women, and although the death rate
was lower in patients over 60 years of age, the SMRs in both SFH men
and women remained significantly elevated. This contrasts with a
“survivor” effects previously reported in the overall register data [14],
where the CHD SMR was not significantly raised at this age than in the
general population.
The Spanish FH Registry has recently reported that the use of the
SFH/NSFH definition did not improve the ability to identify subjects at
highest risk of cardiovascular disease after adjustment for traditional
risk factors [15], although this analysis was based on cross-sectional
CHD data and not prospective longitudinal mortality available from the
UK Register. Our data confirm that the higher CHD risk in SFH vs. NSFH
patients can be explained largely by the higher prevalence of traditional
CHD risk factors in the SFH group and, as such, this definition may be
useful to guide patient clinical management. The strengths of the ana-
lysis presented here is that it is based on a large dataset with essentially
complete follow-up over a period of more than 20 years, with more
than 57,000 person years of exposure. However, a limitation of the data
is that the number of events in later periods is relatively small so the
confidence intervals are large and point estimates need to be inter-
preted cautiously. We also accept that the NSFH category will include a
significant proportion of patients with polygenic hypercholesterolaemia
[16]. A more accurate assessment would be provided by an analysis
restricted to patients with genetically diagnosed FH, however, this data
is not available for the majority of Register patients who were recruited
Table 1
Mean (SD) characteristics in those with severe-FH and non-severe-FH.
Non-severe FH N=947 Severe FH N=1982 p value
Median age [IQR] 44.0 [28.8–57.4] 45.5 (34.5–56.3) 0.017
Previous MI (No (%)) 77 (8.3%, n= 931) 220 (11.3%, n=1943) 0.012
Current/past angina (No (%)) 120 (13.0%, N=923) 374 (19.8, N=1889) <0.001
Diagnosed CHD (No (%)) 166 (17.5%, N=947) 487 (24.6%, N=1982) <0.001
Previous stroke (No (%)) 12 (1.3%, N=945) 20 (1.0%, N=1971) 0.536
Diagnosed diabetes (No (%)) 6 (0.6%, N=946) 20 (1.0%, N=1976) 0.309
Current cigarette smoker (No (%)) 94 (10.2%, N=921) 424 (21.9%, N=1937) <0.001
Systolic BP (mmHg) 129.6 (20.6, N=884) 133.3 (21.0, N=1919) <0.001
Diastolic BP (mmHg) 78.6 (11.1, N=883) 80.5 (11.6, N=1917) <0.001
BMI (kg/m2) 24.4 (4.2, N=830) 25.6 (4.4, N=1762) <0.001
BMI>30 65 (7.8%, N=830) 264 (15.0%, N=1762) <0.001
Total cholesterol (mmol/l) 6.79 (1.41, N=941) 8.39 (2.09, N=1969) <0.001
Triglyceridea (mmol/l) 1.26 (0.8–1.9, N=937) 1.45 (1–2.1, N=1959) <0.001
HDL-C (mmol/l) 1.41 (0.4, N=930) 1.26 (0.35, N=1910) <0.001
LDL-C (mmol/l) 5.00 (1.43, N=924) 6.71 (2.07, N=1892) <0.001
DFH (number (%)) 469 (49.5%, N=947) 1105 (55.8%, N=1982) 0.002
Diagnosed CHD includes previous MI/angina, etc.
a Geom. mean [IQR]. DFH=Simon Broome clinical diagnosis of definite FH (ref).
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in the era before DNA testing was routinely available, and in clinical
practice this is not yet routinely available in the UK nor in the majority
of countries world-wide. However, a mutation can be found in up to
80% of patients with DFH but only 20–30% of those with PFH, most of
whom have a polygenic and not a monogenic cause of their clinical
phenotype [1,2]. In analysis confined to those with a diagnosis of DFH,
the CHD mortality rate was 74% higher in the SFH compared to the
NSFH group, while in the PFH patients, the difference was only 26%
higher, supporting the view that the highest CHD mortality group will
be those with a clinical characteristics of SFH who also carry an FH-
causing mutation.
A limitation of the data is that we do not have current data on
whether the FH patients in the cohort have been treated with statin or
other lipid-lowering agents and only have their lipid levels at regis-
tration, but insights into current treatment practice can be obtained
from the 2010 audit of the management of FH patients [18], which
included the clinics where the patients were originally recruited. Data
was available from the notes of 2324 adult patients with clinical FH;
86% were on statin treatment (33% were treated with atorvastatin,
33% with rosuvastatin, 15% with simvastatin) and 40% were ad-
ditionally being treated with ezetimibe. Mean (SD) untreated LDL-C
was 6.44 (1.77) mmol/l, which by the third clinic visit (at the time of
audit) had been lowered to a mean of 3.60 (1.48) mmol/l, representing
an overall median reduction of 47% from baseline. The remainder were
taking a resin (4%), statin-intolerant (6.8%), declined statin treatment
(1.9%) or were pregnant or breastfeeding (1.7%). We believe that there
is a high likelihood that such treatments were also being given to the SB
cohort of patients, as is recommended by all UK NICE FH and lipid
management guidelines.
These data can be used to estimate what proportion of SFH patients
may qualify for treatment with PCSK9 monoclonal antibody inhibitors.
The NICE Technical Appraisals TA393/394 (https://www.nice.org.uk/
guidance/ta393/ and https://www.nice.org.uk/guidance/ta394/ and
the 2017 updated NICE FH guideline (https://www.nice.org.uk/
guidance/cg71), recommend alirocumab or evolocumab if a patient
has heterozygous-FH with proven CVD, and persistently high LDL-
C>3.5mmol/l despite maximal tolerated lipid-lowering therapy, or
heterozygous-FH with persistently high LDL-C> 5.0mmol/l despite
maximal tolerated lipid-lowering therapy [17]. In the Simon Broome
Register, 25% of patients had CVD at baseline and might qualify de-
pending on their treatment response. We do not have recent on-treat-
ment lipid levels to examine this, but as shown in Supplementary Fig. 2,
in the 2010 National Audit of FH patients [18], 47% had on-treatment
LDL-C>3.5mmol/l suggesting that a maximum of 12% of the register
patients might qualify based on these criteria. The audit data also shows
that 16% had on-treatment LDL-C>5.0mmol/l suggesting that an
additional 12% of the register patients might qualify based on these
criteria. However, since highest CHD risk is seen in the SFH group,
limiting the use of PCSK9i to those who fall into this category would
reduce the number potentially eligible from 24% to around 16%. These
estimates are in line with data from the Spanish FH registry, where 17%
of patients would qualify for PCSK9 inhibition according to European
guidelines [19].
In conclusion, we confirm that the IAS proposed definition of se-
vere-FH identifies a group of male and female patients with a clinical
diagnosis of FH that have a particularly high risk of CHD mortality,
even when on statin treatment. The major contributing factor to this
high risk is the presence of prior CHD, although the utility of the SFH
definition is that it combines information from many different risk
factors. The CHD death rate is significantly elevated in SFH patients at
all ages, but especially in those in the 20–29 year old group and is still
raised in those over the age of 60 years, where a “survivor” effect has
previously been seen in the overall group of treated FH patients. As
shown previously in this dataset, compared to men, women with SFH
do not appear to have benefited from the availability of more potent
statins in the most recent time period examined. While this could be an
artefact due to the relatively small number of events in this later period,
it is possible that these women are not being treated as rigorously as
their male counterparts. This possibility is supported by recent reports
indicating that women are undertreated with statins [20,21]. Overall,
our data suggest that around 16% of patients with a definition of SFH
may qualify for treatment with anti PCSK9 agents, based on current UK
guidelines.
Conflicts of interest
HAWN, NC, PND, BJ, IFWM, and HS have served as consultants to
Fig. 1. SMR CHD deaths.
(A) For severe-FH and non-severe-FH patients post 1991, age 20–79 years. (B)
For severe-FH male and female patients in different age catagories. (C) For
severe-FH male and female patients age 20–79 years in different time periods.
S.E. Humphries et al. Atherosclerosis 281 (2019) 207–212
210
pharmaceutical companies marketing lipid-lowering drugs, and/or
have received travel expenses, payment for speaking at meetings and
funding for research from some of these companies. The other authors
have nothing to declare.
Acknowledgements
We thank Dr Mary Seed for her support of the Register over the last
20 years. The Simon Broome FH register was previously supported by
an unrestricted educational grant from Pfizer, and has previously re-
ceived support from AstraZeneca and Schering-Plough. HAWN and SEH
would like to acknowledge grants RG3008 and RG008/08 from the
British Heart Foundation, BJ the support of an NIHR Clinical
Lectureship and SEH the support of the UCLH NIHR BRC. The sponsors
had no involvement in any aspect of the study or publication.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.atherosclerosis.2018.11.014.
References
[1] S.E. Humphries, T. Cranston, M. Allen, et al., Mutational analysis in UK patients
with a clinical diagnosis of familial hypercholesterolaemia: relationship with
plasma lipid traits, heart disease risk and utility in relative tracing, J. Mol. Med. 84
(2006) 203–214.
[2] B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, et al., Familial hypercholes-
terolaemia is underdiagnosed and undertreated in the general population: guidance
for clinicians to prevent coronary heart disease: consensus statement of the
European Atherosclerosis Society, Eur. Heart J. 34 (2013) 3478–3490a.
[3] J. Slack, Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states,
Lancet 2 (7635) (1969) 1380–1382.
[4] N.J. Stone, R.I. Levy, D.S. Fredrickson, et al., Coronary artery disease in 116 kindred
with familial type II hyperlipoproteinemia, Circulation 49 (1974) 476–488.
[5] C. Gagne, S. Moorjani, D. Brun, et al., Heterozygous familial hypercholesterolemia.
Relationship between plasma lipids, lipoproteins, clinical manifestations and
ischaemic heart disease in men and women, Atherosclerosis 34 (1979) 13–3424.
[6] R.D. Santos, S.S. Gidding, R.A. Hegele, et al., Defining severe familial hypercho-
lesterolaemia and the implications for clinical management: a consensus statement
from the International Atherosclerosis Society Severe Familial
Hypercholesterolemia Panel, Lancet Diabetes Endocrinol. 10 (2016) 850–861.
[7] Scientific Steering Committee on behalf of Simon Broome Familial Hyperlipidaemia
Register Group, The risk of fatal coronary heart disease in familial hypercholes-
terolaemia, B M J 303 (1991) 893–896.
[8] D.J. Betteridge, K. Broome, P.N. Durrington, et al., Scientific Steering Committee on
behalf of the Simon Broome Register Group - mortality in treated heterozygous
familial hypercholesterolaemia: implications for clinical management,
Atherosclerosis 142 (1999) 105–112.
[9] H.A. Neil, M.M. Hawkins, P.N. Durrington, et al., Non-coronary heart disease
mortality and risk of fatal cancer in patients with treated heterozygous familial
hypercholesterolaemia: a prospective registry study, Atherosclerosis 179 (2005)
293–297.
[10] S.E. Humphries, J.A. Cooper, M. Seed, et al., Coronary heart disease mortality in
treated familial hypercholesterolaemia: update of the UK Simon Broome FH reg-
ister, Atherosclerosis 274 (2018) 41–46.
[11] W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative ul-
tracentrifuge, Clin. Chem. 18 (1972) 499–502.
[12] M. Coleman, A. Douglas, C. Hermon, et al., Cohort study analysis with a FORTRAN
computer program, Int. J. Epidemiol. 15 (1986) 134–137.
[13] H.A.W. Neil, V. Seagroatt, D.J. Betteridge, et al., Risk factors for coronary heart
disease in patients with heterozygous familial hypercholesterolaemia, Heart 90
(2004) 1431–1437.
[14] A. Neil, J. Cooper, J. Betteridge, et al., Reductions in all-cause, cancer, and coronary
Table 2
Univariate and multivariate factors associated with CHD mortality in SFH vs. NSFH patients.
Variable Univariate associations with CHD
death
Multivariable model including all
variables.
Model selected using stepwise Cox
regression
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age (years) Per 10 years 1.80 (1.59–2.04) <0.0001 1.49 (1.22–1.82) < 0.0001 1.53 (1.27–1.85) < 0.0001
Sex F:M 0.52 (0.38–0.70) <0.0001 0.53 (0.35–0.79) 0.0002 0.54 (0.36–0.80) 0.002
Ever smoker Y:N 2.67 (1.96–3.63) <0.0001 1.99 (1.33–2.99) 0.001 2.06 (1.38–3.07) 0.0004
Diabetes Y:N 3.48 (1.43–8.46) 0.006 1.74 (0.43–7.14) 0.439
Total cholesterol (mmol/l) Per SD 1.33 (1.15–1.54) <0.0001 1.26 (1.08–1.48) 0.004 1.27 (1.09–1.49) 0.003
BMI (kg/m2) Per SD 1.30 (1.13–1.50) <0.0001 1.14 (0.91–1.42) 0.247
SBP (mmHg) Per SD 1.45 (1.26–1.66) <0.0001 1.12 (0.92–1.37) 0.247
Prior CHD Y:N 8.98 (6.57–12.27) <0.0001 4.34 (2.90–6.51) < 0.0001 4.47 (2.99–6.69) 0.003
Age >40 years at diagnosis Y:N 3.01 (2.25–4.03) <0.0001 1.46 (0.99–2.17) 0.058
Family history early CHD in 1st degree relative Y:N 1.96 (1.16–3.34) 0.012 1.40 (0.75–2.59) 0.290
Diagnosis SFH:NSFH 1.93 (1.33–2.79) 0.0005 1.31 (0.81–2.11) 0.274 1.22 (0.80–1.87) 0.360
Lipoprotein(a) measures not available.
Table 3
Observed and expected deaths from CHD by time period in SFH compared with NSFH for patients aged 20–79 years.
Total Pyrsa From 1 January, 1980 to 31 December, 1991 Total Pyrsa From 1 January, 1992 to December 2008
Observed Expected SMR 95% CI p-value Observed Expected SMR 95% CI p-value
Severe–FH males 1742 11 3.09 356.3 (178,637) <0.0008 13522 69 27.1 254.6 (198, 322) < 0.0001
Severe–FH females 15647 8 1.61 498.3 (215,982) 0.005 11026 30 17.3 173.1 (117,247) 0.008
Non-severe-FH males 458 1 1.58 63.4 (2353) 1 3349 17 9.3 183.1 (107,293) 0.03
Non-severe-FH females 787 2 0.86 231.7 (28,837) 0.42 7134 7 8.0 87.4 (35,180) 0.90
Total Pyrsa From 1 January, 2009 to 31 December, 2015 p value trend
Observed Expected SMR 95% CI p-value
Severe-FH males 5771 16 10.1 158.8 (91,258) 0.10 0.03
Severe–FH females 3816 14 4.0 350.3 (192,588) 0.0001 0.68
Non-severe-FH males 1550 5 2.7 183.5 (60,428) 0.28 0.41
Non-severe-FH females 3400 3 2.1 140.8 (29,411) 0.72 0.96
a Pys= person years exposure.
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